AIM ImmunoTech Inc files provisional patent application for use of Ampligen in Post-COVID-19 Cognitive Dysfunction proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen
OCALA, Fla., Jan. 06, 2021 AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the active AMP-511 Expanded Access Program (EAP) has dosed its first COVID-19 “Long Hauler” patient with the drug Ampligen (rintatolimod), marking a significant milestone in AIM’s efforts to develop an effective therapeutic for people suffering from post-COVID-19 infection chronic fatigue-like symptoms. Additional patients are in the process of being enrolled. The Company also reported it will host an investor conference call on January 12, 2020 at 11AM ET to discuss the AMP-511 trial, believed to be the first clinical trial to treat a patient with COVID-19-induced chronic fatigue-like symptoms, as well as to provide an overall status update on the Company.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed .
AIM ImmunoTech Inc.January 6, 2021 GMT
OCALA, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the active AMP-511 Expanded Access Program (EAP) has dosed its first COVID-19 “Long Hauler” patient with the drug Ampligen (rintatolimod), marking a significant milestone in AIM’s efforts to develop an effective therapeutic for people suffering from post-COVID-19 infection chronic fatigue-like symptoms. Additional patients are in the process of being enrolled. The Company also reported it will host an investor conference call on January 12, 2020 at 11AM ET to discuss the AMP-511 trial, believed to be the first clinical trial to treat a patient with COVID-19-induced chronic fatigue-like symptoms, as well as to provide an overall status update
DGAP-News: AIM I .
DGAP-News: AIM ImmunoTech Inc: AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
vom 24.12.2020, 14:15 Uhr
Bild: pixabay.com
DGAP-News: AIM ImmunoTech Inc / Key word(s): Miscellaneous
AIM ImmunoTech Inc: AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
24.12.2020 / 14:15
The issuer is solely responsible for the content of this announcement.
AIM ImmunoTech Announces that the ME/CFS Clinical Trial of its Drug Ampligen is Open for Enrollment to COVID-19 Long Haulers
Institutional Review Board Authorizes Solicitation for Enrollment of Subjects
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 'Long Haulers' Institutional Review Board Authorizes Public Notification for Potential